Bausch Health Reports Executive Changes, Compensation on Jan 29
Ticker: BHC · Form: 8-K · Filed: Feb 1, 2024 · CIK: 885590
Complexity: simple
Sentiment: neutral
Topics: executive-change, compensation, corporate-governance
TL;DR
**Bausch Health just reported executive changes and compensation arrangements, signaling potential shifts.**
AI Summary
Bausch Health Companies Inc. filed an 8-K on February 1, 2024, reporting an event that occurred on January 29, 2024. This filing indicates a change in leadership or executive compensation, specifically under Item 5.02, "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers." This matters to investors because changes in key personnel or their compensation can signal shifts in company strategy, financial health, or governance, potentially impacting future stock performance.
Why It Matters
Changes in executive leadership or compensation can significantly influence a company's direction and stability, directly affecting investor confidence and the stock's valuation.
Risk Assessment
Risk Level: medium — Changes in executive leadership can introduce uncertainty, but without specific details on the nature of the changes, the immediate risk is moderate.
Analyst Insight
Investors should monitor subsequent filings or company announcements for specific details regarding the executive changes and compensation arrangements to understand their potential impact on Bausch Health's future strategy and performance.
Key Players & Entities
- Bausch Health Companies Inc. (company) — the registrant filing the 8-K
- January 29, 2024 (date) — date of the earliest event reported
- February 1, 2024 (date) — date the 8-K was filed
- 001-14956 (other) — Commission file number
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 29, 2024, as stated in the 'Date of report (Date of earliest event reported)' section.
Which specific items of Form 8-K are being reported by Bausch Health Companies Inc.?
Bausch Health Companies Inc. is reporting under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits).
What is the full legal name of the company filing this 8-K?
The exact name of the registrant as specified in its charter is Bausch Health Companies Inc.
Where are Bausch Health Companies Inc.'s principal executive offices located?
The principal executive offices of Bausch Health Companies Inc. are located at 2150 St. Elzéar Blvd. West, Laval, Québec, Canada H7L 4A8.
What is the Commission file number for Bausch Health Companies Inc.?
The Commission file number for Bausch Health Companies Inc. is 001-14956.
Filing Stats: 625 words · 3 min read · ~2 pages · Grade level 9.8 · Accepted 2024-02-01 17:18:42
Filing Documents
- bhc-20240129.htm (8-K) — 27KB
- ex991-bodprjan2024.htm (EX-99.1) — 9KB
- 0000885590-24-000004.txt ( ) — 167KB
- bhc-20240129.xsd (EX-101.SCH) — 2KB
- bhc-20240129_lab.xml (EX-101.LAB) — 25KB
- bhc-20240129_pre.xml (EX-101.PRE) — 13KB
- bhc-20240129_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On February 1, 2024, the Company issued a press release announcing the foregoing update. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 and Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated February 1, 2024 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 1, 2024 BAUSCH HEALTH COMPANIES INC. By: /s/ Seana Carson Seana Carson Executive Vice President, General Counsel